Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C

American Family Physician

Volumn 72, Issue 4, 2005, Pages 655-662

  Ward, Raymond P ^a,c   Kugelmas, Marcelo ^b,c  

^a St Mary's Family Practice Residency   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ALOPECIA; ANEMIA; ANOREXIA; CLINICAL TRIAL; COUGHING; DEPRESSION; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REDUCTION; DRUG RESPONSE; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER FIBROSIS; MYALGIA; NAUSEA; PATIENT EDUCATION; REVIEW; TERATOGENESIS; VIREMIA;

EID: 23844449325     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003;9:S10-3.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
4. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
6. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
7. Gluud LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database Syst Rev 2005;(1): CD002234.
8. U.S. Preventative Services Task Force. Recommendation statement: screening for hepatitis C in adults. Accessed online July 25, 2005, at: http://www.ahrq.gov/clinic/3rduspstf/hepcscr/hepcrs.htm.
9. Ward RP, Kugelmas M, Libsch KD. Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician 2004;69:1429-36.
10. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
13. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
14. PEG-Intron (Peginterferon alfa-2b) powder for injection (package information). Kenilworth, N.J.: Schering Corp., March 2003. Accessed online July 25, 2005, at: http://www.spfiles.com/pipeg-intron.pdf.
15. Rebetol (ribavirin, USP) capsules (package information). Kenilworth, N.J.: Schering Corp., March 2003. Accessed online July 25, 2005, at: http://www.spfiles.com/pirebetol.pdf.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38: 645-52.
17. Guiding patients through chronic hepatitis C therapy. Kenilworth, N.J.: Schering Corp., 2002.
18. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
19. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
20. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
21. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
22. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36(5 suppl 1):S145-51.
23. Chemello L, Cavalletto L, Bernardinello E, Boccato S, Casarin P, Cavinato F, et al. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVHH Study Group. J Viral Hepat 1999;6:321-7.
24. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504-8.
25. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-14.